Vanguard Group Inc Hille Vax, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Hille Vax, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,573,384 shares of HLVX stock, worth $2.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,573,384

Previous 1,404,198 12.05%

Holding current value

$2.85 Million

Previous $20.3 Million 86.36%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.58 - $14.42 $267,313 - $2.44 Million	169,186 Added 12.05%	1,573,384 $2.77 Million
Q2 2024 Aug 13, 2024	BUY	$11.86 - $15.93 $492,498 - $661,509	41,526 Added 3.05%	1,404,198 $20.3 Million
Q1 2024 May 10, 2024	SELL	$14.15 - $19.75 $1.45 Million - $2.02 Million	-102,168 Reduced 6.97%	1,362,672 $22.7 Million
Q4 2023 Feb 14, 2024	BUY	$10.35 - $17.11 $3.22 Million - $5.32 Million	310,973 Added 26.95%	1,464,840 $23.5 Million
Q3 2023 Nov 14, 2023	BUY	$11.59 - $16.7 $2.9 Million - $4.18 Million	250,200 Added 27.69%	1,153,867 $15.5 Million
Q2 2023 Aug 14, 2023	BUY	$12.93 - $18.76 $5.33 Million - $7.73 Million	412,033 Added 83.81%	903,667 $15.5 Million
Q1 2023 May 15, 2023	SELL	$14.73 - $18.18 $3.09 Million - $3.82 Million	-209,848 Reduced 29.91%	491,634 $8.13 Million
Q4 2022 Feb 10, 2023	BUY	$13.52 - $21.46 $969,762 - $1.54 Million	71,728 Added 11.39%	701,482 $11.7 Million
Q3 2022 Nov 14, 2022	BUY	$10.5 - $22.01 $198,943 - $417,023	18,947 Added 3.1%	629,754 $10.8 Million
Q2 2022 Aug 12, 2022	BUY	$8.7 - $20.18 $5.31 Million - $12.3 Million	610,807 New	610,807 $6.68 Million

Others Institutions Holding HLVX

# of Institutions

Shares Held

36.8M

Call Options Held

Put Options Held

View Full List

About HilleVax, Inc.

Ticker HLVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,427,200
Market Cap $60.5M
Description
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

More about HLVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Hille Vax, Inc. Transaction History